Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: a pooled analysis. by Hartley, BF et al.
Hartley et al. Respiratory Research            (2020) 21:5 
https://doi.org/10.1186/s12931-019-1262-0RESEARCH Open AccessRisk factors for exacerbations and
pneumonia in patients with chronic
obstructive pulmonary disease: a pooled
analysis
Benjamin F. Hartley1, Neil C. Barnes2,3, Sally Lettis4* , Chris H. Compton2, Alberto Papi5 and Paul Jones2,6Abstract
Background: Patients with chronic obstructive pulmonary disease (COPD) are at risk of exacerbations and
pneumonia; how the risk factors interact is unclear.
Methods: This post-hoc, pooled analysis included studies of COPD patients treated with inhaled corticosteroid
(ICS)/long-acting β2 agonist (LABA) combinations and comparator arms of ICS, LABA, and/or placebo. Backward
elimination via Cox’s proportional hazards regression modelling evaluated which combination of risk factors best
predicts time to first (a) pneumonia, and (b) moderate/severe COPD exacerbation.
Results: Five studies contributed: NCT01009463, NCT01017952, NCT00144911, NCT00115492, and NCT00268216.
Low body mass index (BMI), exacerbation history, worsening lung function (Global Initiative for Chronic Obstructive
Lung Disease [GOLD] stage), and ICS treatment were identified as factors increasing pneumonia risk. BMI was the
only pneumonia risk factor influenced by ICS treatment, with ICS further increasing risk for those with BMI <25 kg/m2.
The modelled probability of pneumonia varied between 3 and 12% during the first year. Higher exacerbation risk was
associated with a history of exacerbations, poorer lung function (GOLD stage), female sex and absence of ICS
treatment. The influence of the other exacerbation risk factors was not modified by ICS treatment. Modelled
probabilities of an exacerbation varied between 31 and 82% during the first year.
Conclusions: The probability of an exacerbation was considerably higher than for pneumonia. ICS reduced
exacerbations but did not influence the effect of risks associated with prior exacerbation history, GOLD stage, or female
sex. The only identified risk factor for ICS-induced pneumonia was BMI <25 kg/m2. Analyses of this type may help
the development of COPD risk equations.
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Patients with chronic obstructive pulmonary disease
(COPD) are at risk of exacerbations [1] and pneumonia
[2, 3] and the reduction of future exacerbation risk has
become an important treatment objective [4]. COPD
management is therefore becoming like that of ischemic
heart disease, where the aim is to reduce future risk as
well as relieve current symptoms. The management of
ischemic heart disease benefits from the use of predictive© The Author(s). 2020 Open Access This artic
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rameters to estimate risk of major cardiac events over
the following 10 years. Similar risk equations may be
helpful in COPD management.
Demonstrated risk factors for COPD exacerbations in-
clude low forced expiratory volume in 1 s (FEV1), current
smoking, and a history of previous exacerbations [7–9], al-
though another study found no association between FEV1
and COPD exacerbation risk [10]. Factors associated with
increased pneumonia risk in COPD include: airway ob-
struction [11], low body mass index (BMI) [12, 13], older
age [12, 14, 15], use of psychoanaleptics [11], presence ofle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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trophil counts [17], and use of inhaled corticosteroids
(ICS) [12, 18–21]. The effect of single factors on the risk
of COPD exacerbations and pneumonia has been explored
[12, 14, 15]. Although some individual factors may be rele-
vant, the analysis of multiple factors seems more applic-
able [22]. However, it is not well understood how risk
factors for exacerbations and pneumonia may interact,
and whether, by evaluating multiple factors in combin-
ation, more precise probability estimates of future risk of
exacerbation or pneumonia may be produced. If this were
possible, it might allow the development of risk prediction
equations for COPD patients treated with ICS-containing
therapies.
This post-hoc analysis was designed to evaluate risk
factors for moderate and/or severe exacerbations and
pneumonia in COPD patients treated with ICS. An
individual-patient pooled analysis approach was used,
combining data from multiple studies to improve esti-
mates of the size of the effect.
Methods
Data sources/studies included
Studies sponsored by GlaxoSmithKline plc with individual
patient data were accessed. These were all randomized,
parallel-group, double-blind, clinical trials of at least 52
weeks’ duration in COPD patients treated with the combin-
ation of the ICS fluticasone furoate with the long-acting β2
agonist (LABA) vilanterol, or fluticasone propionate plus
salmeterol combination. They were required to have a
LABA-alone treatment arm, a constant dose of ICS and a
minimum of 100 patients per treatment arm, to ensure a
sufficient number of events. Studies conducted prior to the
TORCH study [23] were excluded, since there may have
been a difference in the awareness of investigators of stud-
ies about the risk of pneumonia before and after that study,
since it was the first to show that ICS-containing regimens
are associated with an increased risk of pneumonia. Pneu-
monia events were identified using adverse event reports,
standardised to the same version of the Medical Dictionary
for Regulatory Activities (MedDRA) and list of adverse
events of special interest (AESI). Finally, the studies had to
have included patients with both moderate and severe/very
severe airflow limitation, to be more representative of the
population for whom ICS/LABA treatment is indicated.
All patients had provided written informed consent to
participate in the included studies and all had been con-
ducted in accordance with the Declaration of Helsinki,
Good Clinical Practice guidelines, and ethical review re-
quirements of participating institutions.
Covariates examined
Only those covariates that were measured in all contrib-
uting studies were included in these analyses. We firstexamined a set of seven covariates that had previously
been used in separate analyses of the individual studies:
age (<65/≥65 years), BMI (<25/≥25 kg/m2), Global Initia-
tive for Chronic Obstructive Lung Disease (GOLD)
grade (I and II: pre-bronchodilator FEV1 ≥50%; III
and IV: pre-bronchodilator FEV1 <50% [4]), number
of exacerbations in the prior year (<2/≥2), history of
smoking (former/current smoker), sex (male/female),
study treatment (with/without ICS). This was termed
the “small covariate set.”
We then repeated the analyses with an expanded set
of nine covariates (“large covariate set”), including race
(Asian/non-Asian) and World Bank Country Income
Group [24]. The World Bank categorizes countries into
four groups: high income (2017 gross national income
per capita [GNIPC] ≥$12,056), upper-middle income
(GNIPC $3896–$12,055), lower-middle income (GNIPC
$996–$3895), and low income (GNIPC ≤$995) [24];
however, for this study these were regrouped further
into two groups (high/non-high income) to give larger
sample sizes in each category. The aim of including race
and income groups was to try to account for possible
differences in standards of care and reporting of pneu-
monia and exacerbations across different countries and
ethnic backgrounds [25].
We refer to these individual covariates as main effects,
but we also examined interaction effects, using all pos-
sible pairwise combinations of the main effects. There
were 21 pairwise interactions derived from the small co-
variate set, and 36 pairwise interactions from the larger
set. Neither study nor region were used as covariates;
study was excluded since it would have no predictive
value for the wider COPD population, and region was
not used owing to collinearity problems with race.
Backward selection
Time to first exacerbation and time to first pneumonia
were analysed separately. A backward elimination
process was used to identify the covariates that best
explained the data: first a Cox proportional hazards
model containing all main and interaction effects was fit-
ted (21 pairwise interactions and 7 main effects in the
smaller set; 36 pairwise interactions and 9 main effects
in the larger set). The least statistically significant main
or interaction effect was then removed from the model
until all remaining main or interaction effects were sig-
nificant (p < 0.1, which is standard for this type of ana-
lysis). Main effects, however, were not removed from the
model if they were present in an interaction effect that
remained in the model.
Subgroup probabilities and hazard ratios
Once the final models were selected, the model-estimated
probability of an event during the first year was shown for
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the model. The probabilities and hazard ratios (HRs) from
the four final models – time to first pneumonia (smaller
set), time to first pneumonia (larger set), time to first
exacerbation (smaller set), and time to first exacerbation
(larger set) – are presented.
Results
Ten studies were identified and screened for eligibility.
Five were excluded because they: lacked a LABA arm
[26]; pre-dated TORCH [27, 28]; had <100 patients per
arm [29]; included only patients with moderate COPD
[30, 31]. Five studies were therefore identified for inclu-
sion (Table 1). Demographic data for the contributing
studies have been published [12, 32, 34] and are sum-
marised in Table 2. Overall, 67% of patients included in
the study were male, 54% had a BMI ≥25 kg/m2, 57% were
former smokers and 54% were aged ≥65 years. The ICS-
treated and non-ICS treated groups were generally well
balanced (Table 2).
Inclusion/exclusion criteria and the definitions used
for moderate and severe exacerbations for each study
are summarised in Additional file 1 Pneumonia model.
In the “small covariate set,” a low BMI (<25 kg/m2),
history of ≥2 exacerbations, worse lung function (GOLD
grades III and IV) and treatment with ICS appeared to
be important factors increasing the risk of pneumonia
(Fig. 1). In summary: pneumonia risk was higher in men
aged ≥65 with a history of <2 exacerbations than youn-
ger men. In addition, the risk of pneumonia associated
with an exacerbation history (≥2 vs <2) was higher for
younger patients (≤64 years) than for older patients (≥65
years). Patients with lower BMI (<25 kg/m2) were at
greater risk of pneumonia on ICS treatment than those
with higher BMI, but ICS treatment did not alter the
risk associated with any of the other factors.Table 1 Numbers of patents in the intent-to-treat (ITT) population a
the current meta-analysis
Study FF/VI
200/25
FF/VI
100/25
FF/VI
50/25
VI
25
Dransfield et al, 2013 [32]
NCT01009463
402 403 408 409
Dransfield et al, 2013 [32]
NCT01017952
409 403 412 409
Anzueto et al, 2009 [33, 34]
NCT00115492
– – – –
Ferguson et al, 2008 [35]
NCT00144911
– – – –
Crim et al, 2009 [12]
NCT00268216
– – – –
Pooled analysis 811 806 820 818
FF/VI fluticasone furoate /vilanterol, FP/SAL fluticasone/salmeterol, ICS inhaled corticThe modelled probability of pneumonia varied be-
tween 3 and 12% during the first year of the studies (the
only common time period) in the identified subgroups
(Fig. 2; Additional file 2). The most at-risk subgroups
were generally older, with a low BMI, a history of exac-
erbations, worse lung function, and treated with ICS.
To further investigate how BMI modifies the pneumonia
risk associated with treatment with ICS, we ran the model
for a second time using a BMI covariate that had 10 levels
(rough deciles), and present the direct adjusted probabilities
of pneumonia during the first year in each BMI by treat-
ment group (ICS vs non-ICS) (Fig. 3). This shows evidence
of a U-shaped curve, with an increased risk of pneumonia
at low and high BMIs in the absence of ICS treatment. A
separation between treatment groups was particularly ap-
parent for patients with BMI <24 kg/m2.
The final model using the “large covariate set” provided
no additional insight, since most of the patients were of
non-Asian ethnicity and from the high-income subgroup
(Additional file 3). It qualitatively replicated the findings
from the “small covariate set,” and all terms in the model
from the small set were retained in the model from the
large set. Income group, race, and various interactions in-
cluding these terms also remained in the “large covariate
set”. Income and race did not affect pneumonia in a quali-
tatively consistent manner.
Exacerbation model
In the “small covariate set,” lack of a history of exacerba-
tions (<2 exacerbations), better lung function (GOLD
grades I and II), male sex, and ICS treatment appeared to
be important factors associated with a lower exacerbation
risk (Fig. 4). The modelled probability of an exacerbation
varied between 31 and 82% during the first year in the
identified subgroups. The most at-risk subgroups were
generally female, with lower BMI (<25 kg/m2), a history ofnd assigned treatment arms in the five contributing studies and
FP/SAL
250/50
SAL
50
FP
500
Placebo Total: ITT ICS treated/
non-ICS treated
– – – – 1622
1213/409
– – – – 1633
1224/409
394 403 – – 797
394/403
394 388 – – 782
394/388
1533 1521 1534 1524 6112
3067/3045
2321 2312 1534 1524 10,946
6292/4654
osteroids
Table 2 Summary of demographic characteristics in the current meta-analysis
Study ICS-treated patients (N = 6292) Non-ICS treated patients (N = 4654) Total (N = 10,946)
Sex, n (%)
Female 2157 (34) 1425 (31) 3582 (33)
Male 4135 (66) 3229 (69) 7364 (67)
Mean age, years (SD)a 64.5 (8.80) 64.8 (8.56) 64.7 (8.70)
Age group, n (%)a
≤ 64years 2945 (47) 2114 (45) 5059 (46)
≥65 years 3347 (53) 2540 (55) 5887 (54)
BMI subgroup, n (%)
<25 kg/m2 2848 (45)† 2217 (48)‡ 5065 (46)§
≥25 kg/m2 3442 (55)† 2435 (52)‡ 5877 (54)§
History of smoking, n (%)
Current smoker 2720 (43)** 1991 (43) 4711 (43)††
Former smoker 3571 (57)** 2663 (57) 6234 (57)††
BMI body mass index, ICS inhaled corticosteroids, SD standard deviation
aAge was imputed when full date of birth was not provided, †N = 6290, ‡N = 4652, §N = 10,942, **N = 6291, ††N = 10,945
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stages III and IV) (Fig. 5).
The final model from the “large covariate set”
differed somewhat from the model selected from
the “small covariate set”: of the interactions found
above, only two were replicated. These were sex by
smoking status (reduction in exacerbation risk for
males vs females was smaller for former smokers)
and BMI by exacerbation history (the increase in ex-
acerbation risk for patients with a history of exacer-
bations was greater in patients with a lower than
higher BMI).Fig. 1 Hazard ratios (95% confidence intervals [CIs]) for pneumonia from se
Global Initiative for Chronic Obstructive Lung Disease, ICS inhaled corticostExacerbations in the pneumonia model
The background to this analysis is a desire to provide
better estimates of possible risk (pneumonia) and pos-
sible benefit (exacerbation reduction), so we tested how
the subgroups selected in the pneumonia model behaved
in terms of prediction of exacerbations. Age and BMI
appeared to have little effect on exacerbation risk. HRs
associated with exacerbation history (≥2 vs <2) appeared
to be larger for exacerbation risk than pneumonia risk.
The HR associated with lung function (GOLD grades
III/IV vs I/II) appeared to be similar for exacerbation
risk and pneumonia risk. Patients with a BMI <25 kg/m2lected seven-covariate pneumonia model. BMI body mass index, GOLD
eroids
Fig. 2 Survival curves (95% CI bands) from selected pneumonia model subgroups showing probability of first pneumonia during year on study
treatment. Cell header line 1: Age (years), sex, Global Initiative for Chronic Obstructive Lung Disease stage; Cell header line 2: Body mass index,
number of exacerbations in the prior year. Numbers of patients presented are subgroup numbers; patients without covariates did not
contribute to the model. All cells are shown in S1. CI confidence interval, ICS inhaled corticosteroids
Fig. 3 Probabilities (95% CIs) of pneumonia during first year by BMI decile (direct adjusted probabilities). BMI body mass index, CI confidence
interval, ICS inhaled corticosteroids
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Fig. 4 Hazard ratios (95% CIs) for exacerbation from selected seven-covariate exacerbation model. BMI body mass index, GOLD Global Initiative
for Chronic Obstructive Lung Disease, ICS inhaled corticosteroids
Fig. 5 Survival curves (95% CI bands) from selected exacerbation model subgroups showing probability of first exacerbation during year on study
treatment. Cell header line 1: age (years), sex, Global Initiative for Chronic Obstructive Lung Disease stage; Cell header line 2: Body mass index,
number of exacerbations in the prior year. Numbers of patients presented are subgroup numbers; patients without covariates did not contribute
to the model. CI confidence interval, ICS inhaled corticosteroids
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(95% confidence interval [CI], 0.81–0.93) for exacerba-
tions (Fig. 6) and 1.83 (95% CI, 1.54–2.17) for pneumo-
nia (Fig. 1). Patients with a BMI ≥25 kg/m2 treated with
an ICS versus non-ICS had an HR of 0.85 (95% CI,
0.79–0.91) for exacerbations (Fig. 6) and 1.32 (95% CI,
1.09–1.59) for pneumonia (Fig. 1). Corresponding prob-
abilities are presented in Fig. 7 and Additional file 4.
Discussion
This analysis explored the interaction between risk
factors for exacerbations and pneumonia in COPD pa-
tients. The results show that modelled probabilities
of an exacerbation over a 1-year period were consid-
erably higher than those for pneumonia (31–82% vs
3–12%, respectively).
The only risk factor for pneumonia influenced by ICS
treatment was BMI, with ICS treatment further increas-
ing risk for patients with BMI <25 kg/m2. A BMI of
<25 kg/m2 has been reported as a pneumonia risk factor
for a study population with COPD and moderate airflow
limitation, along with a prior history of exacerbations
and FEV1 <60% of predicted [36], and our findings ex-
tend this observation across a broader range of airflow
limitation. In the general population, an increased risk of
pneumonia or respiratory infection has been associated
both with obesity [37] and, in women, with being under-
weight [38]. Obesity has also been reported as a risk
factor for influenza/influenza-like disease in patients
undergoing seasonal influenza vaccination [39]. In
COPD, reduced exacerbation frequency has been
described in patients with a BMI ≥24 kg/m2 [40] andFig. 6 Hazard ratios (95% CIs) for exacerbation from selected Cox pneumo
Obstructive Lung Disease, ICS inhaled corticosteroids≥25 kg/m2 [41], although there does not seem to be a
clear association between observed BMI and exacerba-
tions [42]. There have been reports of both low and high
BMI being associated with an increased risk of pneumo-
nia. An association has been described between in-
creased risk of community-acquired pneumonia (CAP)
in patients with lower BMI (median BMI for no CAP
was 23.7 and for CAP was 22.7) [43], while another
study found significantly increased risk of pneumonia in
patients with COPD and a BMI ≥35 kg/m2 [42]. Our
study reported a possible U-shaped effect in patients
with COPD, with pneumonia risk appearing to be in-
creased for patients with the lowest and highest BMIs.
This trend was also observed in the Copenhagen Gen-
eral Population Study, with an increased risk of pneumo-
nia for patients with a BMI <18.5 kg/m2, although this
was not significant due to low numbers [42]. Similarly, a
U-shaped relationship has previously been reported for
BMI and risk of influenza-related pneumonia from a
large meta-analysis in children and adults [44].
When exacerbations were modelled using the same
subgroups found in the model that best explained pneu-
monia risk, BMI did not appear to significantly influence
the ICS treatment effect on exacerbations. Thus, it ap-
pears that patients with BMI <25 kg/m2may have a lower
ratio of benefit to risk from ICS treatment than those
with BMI ≥25 kg/m2. It is possible that the identified
ICS by BMI interaction was driven by the Asian popula-
tion in our analysis, since it had a lower BMI and there
are reported differences in ICS inhaled clearance in
Asian populations compared with those of White/Cau-
casian ethnicity [45]. However, our models could notnia model. BMI body mass index, GOLD Global Initiative for Chronic
Fig. 7 Survival curves (95% CI bands) from selected pneumonia model subgroups showing probability of first exacerbation during year on study
treatment. Cell header line 1: age (years), sex, Global Initiative for Chronic Obstructive Lung Disease stage; Cell header line 2: Body mass index,
number of exacerbations in the prior year. Numbers of patients presented are subgroup numbers; patients without covariates did not contribute
to the model. All cells are shown in S2. CI confidence interval, ICS inhaled corticosteroids
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due to an insufficient number of events, so these rela-
tionships will need to be tested in larger datasets.
Of the interactions found to influence the pneumonia
risk in our analysis: age by sex (p = 0.078), age by exacer-
bation history (p = 0.096), and treatment with ICS by
BMI (p = 0.012), the most significant and clinically plaus-
ible appears to be the interaction between BMI and
treatment with ICS. When the same covariates were
tested as predictors of exacerbations, none of these in-
teractions were significant at the 5% level. Using the ex-
acerbation model from the “small covariate set”, the
most significant interaction was sex by smoking status
(p < 0.001), which was also significant in the “large co-
variate set.” Similarly, the exacerbation history by BMI
interaction (p = 0.052) in the “small covariate set” was
also identified in the “large covariate set,” but other sig-
nificant interactions were not replicated.
The strength of this analysis is the novel exploration
of interactions between risk factors for pneumonia andexacerbations in a large sample size. Full individual-
patient data could be accessed, so there was no bias at
the individual study level in terms of outcomes.
There are, however, limitations associated with the
baseline covariates collected in the individual studies.
Only those covariates measured in all contributing stud-
ies could be included, so this did not, for example, allow
inclusion of biomarkers like eosinophils. The analysis
was also retrospective in nature and the contributing
studies were conducted in different regions and at differ-
ent times. Furthermore, the nature of repeated testing in
the backward elimination procedure does not conserve
the type I error, so results should be considered hypoth-
esis generating. By using binary covariates, we may have
lost information about the subtleties of the effects; how-
ever, binary covariates are simpler to interpret than
multilevel covariates, and unlike the use of continuous
variables they require no assumptions about the linearity
of effect size. Interpretation of correlated covariates
must be done with care, and binary covariates do not
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pooling data from different studies, “study” as a covariate is
generally used to account for variability in effect sizes from
unmeasured covariates that may affect the different studies;
however, due to the study covariate likely having little pre-
dictive value in a wider population of COPD patients, not
recruited to a clinical trial, we omitted this variable. As a re-
sult, we could not account for any differences that it may
measure. We assume that the race and country income
covariates used in the sensitivity analyses with the “large
covariate set” go some way toward accounting for the type
of differences that a study covariate would measure.
Our results should not be considered as providing a
validated risk equation because we did not split the data-
set into two groups: one to develop the model and one
to test it. This was largely due to the relatively small
number of pneumonia events, despite the large number
of participants in the pooled dataset. Further work
should use individual patient-level data from a broader
range of studies, with a wider range of covariates includ-
ing biomarkers, and not be restricted to trials sponsored
by a single pharmaceutical company.
Conclusions
The hypothesis-generating methods used for this analysis
may be applicable to future analyses designed to develop
risk equations for exacerbation benefit and treatment-
associated pneumonia risk in COPD. They will require
testing and validation in other, larger datasets.
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definition of a COPD exacerbation, and pneumonia adverse event
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subgroups (based on the nine-covariate model).
Additional file 4. Survival curves (95% CI bands) from selected
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